The global biomarkers market is expected to reach USD 78.1 billion in 2026 from USD 43.1 billion in 2021 at a CARG of 12.6%. Growth in the biomarkers market is mainly driven by factors such as the growing importance of companion diagnostics, increasing prevalence of cancer worldwide, growing funding activities for biomarker research, and product innovations.
“By disease indications segment, the cancer segment accounted for the fastest-growing segment of the biomarkers market”
Based on disease indication, the biomarkers market is segmented into cancer, infectious diseases, neurological disorders, immunological disorders, cardiovascular disorders, and other disease indications. The cancer segment is expected to be the fastest-growing segment of the biomarkers market during the forecast period. The growth of this segment is primarily due to the increasing prevalence of cancer globally and the growing application of biomarkers in cancer diagnostics.
“By application, the diagnostics segment accounted for the largest share of the biomarkers market”
Based on application, the biomarkers market is segmented into diagnostics, drug discovery & development, personalized medicine, disease risk assessment, and other applications. In 2020, the diagnostics segment accounted for the largest share of the application segment in the biomarkers market. The use of biomarkers for the diagnosis of multiple diseases, including cancer, infectious diseases, cardiovascular disorders, and neurological disorders, is on the rise. The increasing use of biomarkers is a major factor that drives the growth of the diagnostics segment of the biomarkers market.
“Asia Pacific: The fastest-growing region in the biomarkers market.”
The biomarkers market in the Asia Pacific region is projected to register the highest growth during the forecast period. The growth of this segment is primarily due to the increasing use of biomarkers for diagnostic purposes, the growing prevalence of chronic diseases, favorable government initiatives, and the growing focus on genomic & proteomic research projects.
“North America: the largest share of the biomarkers market”
North America accounted for the largest share of the market. The large share of this region can be attributed to the growing use of biomarkers in personalized medicine, various growth strategies adopted by key players with established pharmaceutical companies in this region, and a higher adoption rate of biomarkers for disease diagnostics, majorly in cancer diagnosis.
Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:
- By Respondent– Supply Side- 70%, Demand Side-30%
- By Designation- CXOs and Directors- 30%, Executives - 25%, Mangers - 45%
- By Region- North America - 40%, Europe - 25%, APAC – 20%, RoW- 15%
The biomarkers market is dominated by a few globally established players such as F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), QIAGEN N.V. (Netherlands), PerkinElmer, Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), ENZO BIOCHEM, INC. (US), Charles River Laboratories International, Inc. (US), Eurofins Scientific S.E. (Luxembourg), Meso Scale Diagnostics, LLC. (US), StressMarq Biosciences Inc. (US), DiaMetra Srl (Italy), Signosis, Inc. (US), bioM?rieux SA (France), Axon Medchem BV (Netherlands), EKF Diagnostics Holdings, Plc (UK), MicroConstants, Inc. (US), NorthEast BioAnalytical Laboratories LLC. (US), Q2 Solutions LLC. (US), JSR Life Sciences, LLC (US), BioAgilytix Labs (US), Celerion (US), AnyGenes (US), and BiomarkerBay B. V. (Netherlands).
The report segments the biomarkers market based on region (Asia Pacific, Europe, North America, and Rest of the World), product (consumables services, software), type (safety biomarkers, efficacy biomarkers [predictive biomarkers, surrogate biomarkers, pharmacodynamics biomarkers, prognostic biomarkers], and validation biomarkers, application (diagnostics, drug discovery & development
Personalized medicine, disease risk assessment and other applications), and disease indications (cancer
[solid biopsy, liquid biopsy], infectious diseases, immune disorders, neurological disorders, cardiovascular disorders, and other disease indications). The report also provides a comprehensive review of market drivers, restraints opportunities, challenges and trends in the biomarkers market.
Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the biomarkers market and provides them information on key market drivers, restraints, challenges, and opportunities.